Summary

The global market for Long-Acting Insulin Analogue was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.

North American market for Long-Acting Insulin Analogue was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long-Acting Insulin Analogue was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Long-Acting Insulin Analogue was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global key companies of Long-Acting Insulin Analogue include Novo Nordisk, Sanofi, Eli Lilly and Company, Gan and Lee Pharmaceuticals, The United Laboratories International Holdings, Tonghua Dongbao Pharmaceutical, etc. In 2024, the global five largest players hold a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Long-Acting Insulin Analogue, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Long-Acting Insulin Analogue by region & country, by Type, and by Application.
The Long-Acting Insulin Analogue market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-Acting Insulin Analogue.

Market Segmentation
By Company
Novo Nordisk
Sanofi
Eli Lilly and Company
Gan and Lee Pharmaceuticals
The United Laboratories International Holdings
Tonghua Dongbao Pharmaceutical
Segment by Type
Insulin Glargine
Insulin Detemir
Insulin Degludec
Segment by Application
Type 2 Diabetes
Type 1 Diabetes
Gestational Diabetes
Other Diabetes
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Long-Acting Insulin Analogue manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Long-Acting Insulin Analogue in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Long-Acting Insulin Analogue in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Long-Acting Insulin Analogue Product Introduction
1.2 Global Long-Acting Insulin Analogue Market Size Forecast
1.2.1 Global Long-Acting Insulin Analogue Sales Value (2020-2031)
1.2.2 Global Long-Acting Insulin Analogue Sales Volume (2020-2031)
1.2.3 Global Long-Acting Insulin Analogue Sales Price (2020-2031)
1.3 Long-Acting Insulin Analogue Market Trends & Drivers
1.3.1 Long-Acting Insulin Analogue Industry Trends
1.3.2 Long-Acting Insulin Analogue Market Drivers & Opportunity
1.3.3 Long-Acting Insulin Analogue Market Challenges
1.3.4 Long-Acting Insulin Analogue Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Long-Acting Insulin Analogue Players Revenue Ranking (2024)
2.2 Global Long-Acting Insulin Analogue Revenue by Company (2020-2025)
2.3 Global Long-Acting Insulin Analogue Players Sales Volume Ranking (2024)
2.4 Global Long-Acting Insulin Analogue Sales Volume by Company Players (2020-2025)
2.5 Global Long-Acting Insulin Analogue Average Price by Company (2020-2025)
2.6 Key Manufacturers Long-Acting Insulin Analogue Manufacturing Base and Headquarters
2.7 Key Manufacturers Long-Acting Insulin Analogue Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Long-Acting Insulin Analogue
2.9 Long-Acting Insulin Analogue Market Competitive Analysis
2.9.1 Long-Acting Insulin Analogue Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Long-Acting Insulin Analogue Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Insulin Analogue as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Insulin Glargine
3.1.2 Insulin Detemir
3.1.3 Insulin Degludec
3.2 Global Long-Acting Insulin Analogue Sales Value by Type
3.2.1 Global Long-Acting Insulin Analogue Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Long-Acting Insulin Analogue Sales Value, by Type (2020-2031)
3.2.3 Global Long-Acting Insulin Analogue Sales Value, by Type (%) (2020-2031)
3.3 Global Long-Acting Insulin Analogue Sales Volume by Type
3.3.1 Global Long-Acting Insulin Analogue Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Long-Acting Insulin Analogue Sales Volume, by Type (2020-2031)
3.3.3 Global Long-Acting Insulin Analogue Sales Volume, by Type (%) (2020-2031)
3.4 Global Long-Acting Insulin Analogue Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Type 2 Diabetes
4.1.2 Type 1 Diabetes
4.1.3 Gestational Diabetes
4.1.4 Other Diabetes
4.2 Global Long-Acting Insulin Analogue Sales Value by Application
4.2.1 Global Long-Acting Insulin Analogue Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Long-Acting Insulin Analogue Sales Value, by Application (2020-2031)
4.2.3 Global Long-Acting Insulin Analogue Sales Value, by Application (%) (2020-2031)
4.3 Global Long-Acting Insulin Analogue Sales Volume by Application
4.3.1 Global Long-Acting Insulin Analogue Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Long-Acting Insulin Analogue Sales Volume, by Application (2020-2031)
4.3.3 Global Long-Acting Insulin Analogue Sales Volume, by Application (%) (2020-2031)
4.4 Global Long-Acting Insulin Analogue Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Long-Acting Insulin Analogue Sales Value by Region
5.1.1 Global Long-Acting Insulin Analogue Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Long-Acting Insulin Analogue Sales Value by Region (2020-2025)
5.1.3 Global Long-Acting Insulin Analogue Sales Value by Region (2026-2031)
5.1.4 Global Long-Acting Insulin Analogue Sales Value by Region (%), (2020-2031)
5.2 Global Long-Acting Insulin Analogue Sales Volume by Region
5.2.1 Global Long-Acting Insulin Analogue Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Long-Acting Insulin Analogue Sales Volume by Region (2020-2025)
5.2.3 Global Long-Acting Insulin Analogue Sales Volume by Region (2026-2031)
5.2.4 Global Long-Acting Insulin Analogue Sales Volume by Region (%), (2020-2031)
5.3 Global Long-Acting Insulin Analogue Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Long-Acting Insulin Analogue Sales Value, 2020-2031
5.4.2 North America Long-Acting Insulin Analogue Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Long-Acting Insulin Analogue Sales Value, 2020-2031
5.5.2 Europe Long-Acting Insulin Analogue Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Long-Acting Insulin Analogue Sales Value, 2020-2031
5.6.2 Asia Pacific Long-Acting Insulin Analogue Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Long-Acting Insulin Analogue Sales Value, 2020-2031
5.7.2 South America Long-Acting Insulin Analogue Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Long-Acting Insulin Analogue Sales Value, 2020-2031
5.8.2 Middle East & Africa Long-Acting Insulin Analogue Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Long-Acting Insulin Analogue Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Long-Acting Insulin Analogue Sales Value
6.2.1 Key Countries/Regions Long-Acting Insulin Analogue Sales Value, 2020-2031
6.2.2 Key Countries/Regions Long-Acting Insulin Analogue Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Long-Acting Insulin Analogue Sales Value, 2020-2031
6.3.2 United States Long-Acting Insulin Analogue Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Long-Acting Insulin Analogue Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Long-Acting Insulin Analogue Sales Value, 2020-2031
6.4.2 Europe Long-Acting Insulin Analogue Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Long-Acting Insulin Analogue Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Long-Acting Insulin Analogue Sales Value, 2020-2031
6.5.2 China Long-Acting Insulin Analogue Sales Value by Type (%), 2024 VS 2031
6.5.3 China Long-Acting Insulin Analogue Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Long-Acting Insulin Analogue Sales Value, 2020-2031
6.6.2 Japan Long-Acting Insulin Analogue Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Long-Acting Insulin Analogue Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Long-Acting Insulin Analogue Sales Value, 2020-2031
6.7.2 South Korea Long-Acting Insulin Analogue Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Long-Acting Insulin Analogue Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Long-Acting Insulin Analogue Sales Value, 2020-2031
6.8.2 Southeast Asia Long-Acting Insulin Analogue Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Long-Acting Insulin Analogue Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Long-Acting Insulin Analogue Sales Value, 2020-2031
6.9.2 India Long-Acting Insulin Analogue Sales Value by Type (%), 2024 VS 2031
6.9.3 India Long-Acting Insulin Analogue Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Novo Nordisk
7.1.1 Novo Nordisk Company Information
7.1.2 Novo Nordisk Introduction and Business Overview
7.1.3 Novo Nordisk Long-Acting Insulin Analogue Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Novo Nordisk Long-Acting Insulin Analogue Product Offerings
7.1.5 Novo Nordisk Recent Development
7.2 Sanofi
7.2.1 Sanofi Company Information
7.2.2 Sanofi Introduction and Business Overview
7.2.3 Sanofi Long-Acting Insulin Analogue Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Sanofi Long-Acting Insulin Analogue Product Offerings
7.2.5 Sanofi Recent Development
7.3 Eli Lilly and Company
7.3.1 Eli Lilly and Company Company Information
7.3.2 Eli Lilly and Company Introduction and Business Overview
7.3.3 Eli Lilly and Company Long-Acting Insulin Analogue Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Eli Lilly and Company Long-Acting Insulin Analogue Product Offerings
7.3.5 Eli Lilly and Company Recent Development
7.4 Gan and Lee Pharmaceuticals
7.4.1 Gan and Lee Pharmaceuticals Company Information
7.4.2 Gan and Lee Pharmaceuticals Introduction and Business Overview
7.4.3 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Product Offerings
7.4.5 Gan and Lee Pharmaceuticals Recent Development
7.5 The United Laboratories International Holdings
7.5.1 The United Laboratories International Holdings Company Information
7.5.2 The United Laboratories International Holdings Introduction and Business Overview
7.5.3 The United Laboratories International Holdings Long-Acting Insulin Analogue Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 The United Laboratories International Holdings Long-Acting Insulin Analogue Product Offerings
7.5.5 The United Laboratories International Holdings Recent Development
7.6 Tonghua Dongbao Pharmaceutical
7.6.1 Tonghua Dongbao Pharmaceutical Company Information
7.6.2 Tonghua Dongbao Pharmaceutical Introduction and Business Overview
7.6.3 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Product Offerings
7.6.5 Tonghua Dongbao Pharmaceutical Recent Development
8 Industry Chain Analysis
8.1 Long-Acting Insulin Analogue Industrial Chain
8.2 Long-Acting Insulin Analogue Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Long-Acting Insulin Analogue Sales Model
8.5.2 Sales Channel
8.5.3 Long-Acting Insulin Analogue Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer